Aomics GmbH

Aomics GmbH is a German startup that focuses on boosting immuno-oncology research with cost-efficient biometric solutions for SMEs. The company's slogan "Analytics-driven risk reduction in immunotherapy development" succinctly captures its mission. Aomics' approach to reducing risks in the rapidly evolving field of immunotherapy revolves around analytics-driven risk reduction powered by advanced multi-omics data analytics and specialized immuno-informatics. By integrating and analyzing diverse data sets, including genomics, transcriptomics, proteomics, and metabolomics, the company uncovers comprehensive insights into immune response mechanisms. Aomics' immuno-informatics focus allows them to predict potential immune-related adverse effects (irAEs), identify biomarkers, and optimize therapeutic strategies, ensuring that every step in the immunotherapy development process is backed by precise, data-driven decisions. This holistic approach not only accelerates the path to innovative treatments but also enhances their safety and efficacy, ultimately transforming patient outcomes. Founded in 2019, Aomics operates in the biotechnology, healthcare, and information technology industries, with its headquarters based in Germany. The company secured a grant investment on 26th August 2021. With a focus on oncology studies, they provide comprehensive statistical consulting, programming, and CDM services to support further clinical developments of new therapies. Although specific details about the investors behind the last investment round are not mentioned, Aomics GmbH's innovative approach positions it at the forefront of advancing immuno-oncology research and development.